Synergistic Combinations for Enhanced GVHD Risk Reduction

This inventive concept integrates alpha-1 antitrypsin administration with distinct technologies, such as AI, IoT, blockchain, and novel biomaterials, to create a more powerful system for reducing the risk of onset of acute graft versus host disease after hematopoietic cell transplantation.

The original patent disclosed methods for reducing the risk of development of graft versus host disease (GVHD) in patients receiving hematopoietic cell transplantation (HCT) by administering alpha-1 antitrypsin (A1AT). However, these methods have limitations in terms of personalized risk assessment, real-time monitoring, and optimized dosing schedules. The new inventive concept addresses these limitations by integrating A1AT administration with advanced technologies to provide a more comprehensive and effective solution.

The new inventive concept comprises five synergistic combinations: (1) a wearable device and AI-powered analytics module for predicting GVHD risk and triggering A1AT administration; (2) a machine learning-based method for personalized GVHD risk assessment and prevention; (3) a blockchain-based system for tracking and verifying A1AT administration and GVHD risk assessment; (4) a nanoparticle-based biomaterial for delivering A1AT with enhanced bioavailability and reduced immunogenicity; and (5) an IoT-enabled health monitoring system for tracking patient health metrics and identifying early GVHD warning signs. These combinations enable real-time monitoring, personalized risk assessment, and optimized dosing schedules, leading to improved GVHD risk reduction.

The new claims introduce novel combinations of A1AT administration with distinct technologies, which are not obvious from the original patent. The integration of AI, IoT, blockchain, and novel biomaterials with A1AT administration provides a non-obvious solution that addresses the limitations of the original patent.

Alternative embodiments of the inventive concept may include using different types of wearable devices, AI algorithms, or biomaterials. Variations may also include integrating A1AT administration with other technologies, such as virtual reality or natural language processing, to enhance patient engagement and outcomes.

The inventive concept has significant commercial potential in the healthcare industry, particularly in the fields of hematopoietic cell transplantation and immunotherapy. The target market includes hospitals, research institutions, and pharmaceutical companies involved in GVHD risk reduction and management.